Influx of adoptive cell therapies may be on the horizon

Adoptive cell therapy is a type of immunotherapy comprising cells that are engineered and expanded ex vivo and administered to stimulate the immune system and kill tumour cells or other diseased cells. There are three main categories of adoptive cell therapies: tumour-infiltrating lymphocyte (TIL) immunotherapy, natural killer (NK) cell immunotherapy, and T cell immunotherapy. The most popular type of adoptive cell therapy by far is T cell immunotherapy, specifically chimeric antigen receptor (CAR)-T cell therapy, which accounts for 55% of all adoptive cell therapy trials, according to data obtained from GlobalData’s Trials Intelligence platform.